Insurance Type Linked to Surgery Delay in Melanoma

Share this content:
Insurance Type Linked to Surgery Delay in Melanoma
Insurance Type Linked to Surgery Delay in Melanoma

WEDNESDAY, Oct. 4, 2017 (HealthDay News) -- Patients diagnosed with melanoma are more likely to have treatment delays if they are nonwhite or on Medicaid, while delays are less likely for patients diagnosed or treated by a dermatologist, according to a study published online Oct. 4 in JAMA Dermatology.

Adewole S. Adamson, M.D., M.P.P., from the University of North Carolina at Chapel Hill, and colleagues conducted a retrospective cohort study of patients who were diagnosed with melanoma to assess factors associated with delays between diagnosis and surgery. The researchers used data from the North Carolina Cancer Registry linked to administrative claims from Medicare, Medicaid, and private insurance. Data were included for 7,629 patients: 48 percent Medicare, 48 percent privately insured, and 4 percent Medicaid.

The researchers found that the likelihood of experiencing a delay in definitive surgery was lowest for privately insured patients, followed by Medicare and Medicaid patients (14, 17, and 24 percent, respectively). The risk of surgical delay was significantly increased in patients with Medicaid versus private insurance after demographic adjustment (risk ratio, 1.36). Nonwhite patients were more likely to have delays (risk ratio, 1.38). If the physician performing the surgery or the diagnosing clinician was a dermatologist versus a nondermatologist, surgical delays were less likely (risk ratio, 0.82 and 0.81, respectively).

"A reduction in delays in melanoma surgery could be achieved through better access to specialty care and cross-disciplinary coordination," the authors write.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »